Karimi-Zarchi Mojgan, Dehshiri-Zadeh Najmeh, Sekhavat Leili, Nosouhi Fahime
Department of Obstetrics and Gynecology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.; Recurrent Abortion Research Center, Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Department of Obstetrics and Gynecology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Int J Reprod Biomed. 2016 Nov;14(11):713-718.
Cancer antigen 125 (CA-125) is a glycoprotein biomarker that is used in women with pelvic masses such as endometriosis and maybe is useful in practice of patients suspicious to endometriosis.
The aim of this study was to evaluate the association between preoperative serum CA-125 levels and clinic pathological characteristic in women with endometriosis, and find out the best serum CA-125 levels cut-off in pre and post menopause women.
Serum CA-125 levels in 87 women aged 21-54 years suspected to endometriosis with pelvic pain, dysmenorrhea, or dyspareunia were measured preoperatively. Also the association between clinic pathological characteristic and serum CA-125 level were analyzed.
The mean age of women was 32.22±6.91. The mean serum CA-125 level was 49.93±4.30 U/mL. There was a significant correlation between the endometriosis stage, lesion size, adhesion score and preoperative CA-125 plasma concentration. However, we did not found significant differences in age, marital status, patient's complaints, and pelvic pain associated to Ca125 serum level. The suggested preoperative serum cut-off levels in premenopausal and postmenopausal patients were 37 U/ml and 35 U/ml, respectively.
According to the results, preoperative serum CA-125 is an important predictor for patients with endometriosis and it should be taken into consideration when surgical management is suspected, especially if stage of disease, lesion size and adhesion score are undertaken.
癌抗原125(CA-125)是一种糖蛋白生物标志物,用于患有盆腔肿块(如子宫内膜异位症)的女性,可能对疑似子宫内膜异位症的患者的临床实践有用。
本研究旨在评估子宫内膜异位症女性术前血清CA-125水平与临床病理特征之间的关联,并找出绝经前后女性血清CA-125的最佳截断水平。
对87名年龄在21-54岁、疑似患有子宫内膜异位症且伴有盆腔疼痛、痛经或性交困难的女性术前测定血清CA-125水平。同时分析临床病理特征与血清CA-125水平之间的关联。
女性的平均年龄为32.22±6.91岁。血清CA-125平均水平为49.93±4.30 U/mL。子宫内膜异位症分期、病变大小、粘连评分与术前CA-125血浆浓度之间存在显著相关性。然而,我们未发现年龄、婚姻状况、患者主诉以及与Ca125血清水平相关的盆腔疼痛方面存在显著差异。绝经前和绝经后患者术前血清的建议截断水平分别为37 U/ml和35 U/ml。
根据结果,术前血清CA-125是子宫内膜异位症患者的重要预测指标,在怀疑进行手术治疗时应予以考虑,尤其是在评估疾病分期、病变大小和粘连评分时。